Intelligence reports are often deemed “worthless,” however, this dismissal often stems from a lack of understanding on how to use them. These reports provide critical insights and information by distilling and organising data but require interpretation and application within specific contexts to become actionable strategies. Thus, the value lies not in the reports themselves, but in the expertise to leverage them correctly.
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But
